OmicScouts

What OmicScouts does

OmicScouts is a Munich-based contract research organization (CRO) founded in 2014 that specializes in mass spectrometry-based proteomics for drug and biomarker discovery. The company operates a portfolio of more than 15 proprietary platforms spanning proteome profiling (ProteomeScout, 10,000+ proteins), reactive cysteine mapping (CysScout, 46,000+ indexed sites across 9,000+ proteins), target identification (TargetScout), kinase selectivity profiling (KinomeScout, ~300 kinases), thermal proteome profiling (SideScout, patent pending), transcription factor capture (NucleoBeads), phosphoproteomics (SignallingScout), protein turnover (TurnoverScout), and targeted quantification (BiomarkerScout). The company also markets a Protein Turnover Atlas data product covering >14,000 human proteins across 30+ cell lines, available for in-licensing.

The business model is a professional services CRO operation with direct B2B sales to enterprise pharmaceutical and biotechnology clients, augmented by academic research collaborations and a recurring data-licensing stream from the Protein Turnover Atlas. Pricing is quote-based and not publicly disclosed. Scientific credibility is anchored by co-founders Prof. Bernhard Kuster (TUM, former Cellzome/GSK VP), Mathias Wilhelm (first author on the 2014 Nature human proteome paper), and CEO Dr. Hannes Hahne, with the team collectively co-authoring more than 150 publications in Nature, Science, NEJM, and The Lancet.

On March 5, 2025, OmicScouts was acquired by Momentum Biotechnologies, a US-based proteomics services peer. Post-acquisition, OmicScouts operates as 'OmicScouts, a Momentum Biotechnologies Company' from its Freising laboratory (Lise-Meitner-Straße 30, Germany), with Hannes Hahne elevated to President of the combined proteomics franchise. The acquisition is positioned to give the combined entity cross-Atlantic geographic reach and a broader assay portfolio spanning OmicScouts' wet-lab proteomics and Momentum's data software stack.

Name

OmicScouts

Legal name

OmicScouts GmbH

Website

https://omicscouts.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

11–50 employees

Short description

OmicScouts is a Munich-based CRO founded in 2014 that delivers mass spectrometry-based proteomics services and 15+ proprietary assay platforms to pharmaceutical, biotechnology, and academic clients for drug and biomarker discovery; acquired by Momentum Biotechnologies in March 2025.

Ownership category

akta.pro rank

Product category

Proteomics Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Mass spectrometry proteomics
• Contract research services
• Target identification
• Biomarker discovery
• Chemical proteomics

Headquarters

HQ city

Freising

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Contract Research Services: OmicScouts provides mass spectrometry-based proteomics services as a contract research organization (CRO). Services include chemical proteomics, target identification, selectivity profiling, biomarker discovery, and custom proteomics solutions for pharmaceutical and biotech clients. Revenue is generated through project-based service contracts with pharmaceutical and biotechnology companies for drug discovery support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

OmicScouts operates as a contract research organization (CRO) providing mass spectrometry-based proteomics services for drug and biomarker discovery. The company delivers end-to-end chemical proteomics, target identification, selectivity profiling, and biomarker discovery solutions to pharmaceutical and biotechnology clients using a suite of proprietary platforms including ProteomeScout, CysScout, TargetScout, KinomeScout, SideScout, NucleoBeads, SignallingScout, TurnoverScout, and BiomarkerScout. Services are project-based, supported by computational biology integration and experienced scientific consulting.

Product overview

OmicScouts offers a comprehensive portfolio of mass spectrometry-based proteomics technologies and services organized as distinct branded platforms. The core offerings include ProteomeScout for deep proteome profiling, CysScout for reactive cysteine mapping, TargetScout for target selectivity profiling, KinomeScout for kinase analysis, SideScout for thermal proteome profiling, NucleoBeads for transcription factor analysis, SignallingScout for phosphoproteomics, TurnoverScout for protein synthesis/degradation studies, and BiomarkerScout for targeted quantification. These platforms are complemented by Computational Biology services for multi-omics data integration and Custom Solutions for project-specific needs. The company operates as a contract research organization (CRO) providing these technologies across solution areas including drug discovery, biomarker discovery, disease and systems biology, and immuno-oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• ProteomeScout Deep and rapid proteome profiling technology enabling routine quantification of more than 10,000 proteins per sample with high accuracy and precision. Supports TMT, DIA, and SILAC workflows and a high-throughput variant (ProteomeScout HT) for screening hundreds to thousands of compounds.
• CysScout Quantitative chemoproteomics platform for comprehensive mapping of reactive cysteines. Identifies more than 20,000 distinct reactive cysteine sites for over 8,000 proteins; database indexes over 46,000 reactive cysteine sites for more than 9,000 proteins. Used for target identification of molecular glues, PROTACs, and covalent compounds.
• TargetScout Selectivity and affinity profiling technology that reveals and verifies specific cellular targets of small molecules under physiological conditions with native proteins. Provides target-specific IC50 information and proteome-wide selectivity analysis in a target-class agnostic manner.
• KinomeScout Kinase-binding matrix technology measuring potency of compounds against approximately 300 different kinases and ATP-binding proteins without requiring labels on drug or protein. Used for selectivity profiling and target biomarker discovery.
• SideScout Biophysical protein stability assay (Thermal Protein Profiling) enabling proteome-wide target identification without labeling. Monitors protein-ligand interactions under physiological conditions in living cells or lysates for up to 9,000 proteins. Patent pending.
• NucleoBeads Quantitative chemical proteomics technique using double-strand DNA oligonucleotide probes to capture and quantify more than 300 transcription factors and complexes (e.g., P53, NFkB, MYC). Used to identify functional inhibitors of transcription factors and other DNA-binding proteins.
• SignallingScout Comprehensive profiling of dynamic phosphorylation events across up to hundreds of samples. Reveals cellular modes of action for kinase inhibitors and identifies pharmacodynamic signatures for therapeutic kinase inhibition.
• TurnoverScout Technology tracking protein synthesis and degradation independently and simultaneously for more than 8,000 cellular proteins in parallel using pulse-chase labelling with heavy amino acids. Supports characterization of PROTACs and other protein degraders.
• BiomarkerScout Targeted proteomics technology based on Parallel Reaction Monitoring (PRM) and stable isotope labelled peptide standards enabling accurate, sensitive, and multiplexed quantification of up to 100 selected proteins across hundreds of samples.
• Computational Biology Integration and analysis of multiple molecular profiling (omics) layers. Includes genomics, statistics, cluster analyses, machine learning approaches, feature selection, multivariate statistics, and pathway and network analyses.
• Custom Solutions Customized experimental approaches including proteogenomic studies, post-translational modification analyses (glycosylation, acetylation, ubiquitinylation), protein-protein interaction studies, and development of MS-based assays for specific proteins.
• Protein Turnover Atlas Comprehensive protein turnover resource covering more than 14,000 human proteins (over 70% of the human proteome) across 30+ diverse cancer cell lines, primary cells, and iPSC-derived neurons. Available for in-licensing.

Quantifiable outcome

• Identification of >46,000 reactive cysteine sites for >9,000 proteins
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• Momentum BiotechnologiesflagshipStrategic or Co-development Partner · 5 March 2025Momentum Biotechnologies completed the acquisition of OmicScouts GmbH, a Munich-based CRO specializing in mass spectrometry-based proteomics. The acquisition expands Momentum's service offerings and enables geographic expansion into the European market. OmicScouts now operates as 'OmicScouts, a Momentum Biotechnologies Company'. CEO Dr. Hannes Hahne transitioned to President and member of Momentum's global executive leadership team.
• TUM Chair of Proteomics and BioanalyticscoreStrategic or Co-development Partner · 28 August 2020Collaborative partnership for SARS-CoV-2 protein:RNA interaction screening platform. Received grant funding from Bayrische Forschungsstiftung for systematic investigation of host and SARS-CoV-2 protein and RNA interactions.
• TUM Institute of VirologycoreStrategic or Co-development Partner · 28 August 2020Collaborative partnership for SARS-CoV-2 protein:RNA interaction screening platform with grant funding from Bayrische Forschungsstiftung.
• ZIM Network Proteomics4FuturecoreStrategic or Co-development PartnerZIM cooperation network officially started December 2020 with 12 partners from research institutions and companies. Goal: accelerate industrial dissemination of mass spectrometry-based proteomics through new methods and workflow standardization. Funded by Central Innovation Program for Medium-Sized Enterprises of Federal Ministry of Economics and Energy.
• MSAID GmbHminorStrategic or Co-development PartnerMember of ZIM Network Proteomics4Future focusing on proteomics technology development and standardization.
• PreOmics GmbHminorStrategic or Co-development PartnerMember of ZIM Network Proteomics4Future focusing on proteomics sample preparation technology.
• Immatics Biotechnologies GmbHminorStrategic or Co-development PartnerMember of ZIM Network Proteomics4Future focused on immunotherapy and cancer research.
• Technical University of Munich (Institute for General Pathology and Pathological Anatomy)coreStrategic or Co-development PartnerMember of ZIM Network Proteomics4Future. Close academic collaboration with OmicScouts co-founders who are affiliated with TUM.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Eurofins Scientific: Global laboratory services conglomerate offering biomarker, proteomics, and pharma testing services. Operates at much larger scale but competes in adjacent service categories for pharma clients.
• Evotec SE: Large German-based drug discovery CRO offering comprehensive services including proteomics and biomarker discovery. Provides broader drug discovery platform but overlaps on target identification and validation work.
• Charles River Laboratories: Major preclinical and discovery CRO with broad service portfolio. While not specialized in proteomics, competes for similar pharma R&D budgets and has expanded into adjacent specialty analytical services.
• Cellzome (GSK): Chemical proteomics pioneer now part of GSK where co-founder Bernhard Kuster previously served as VP. Direct historical connection to OmicScouts' founding expertise; operates as internal GSK capability rather than external CRO.
• Thermo Fisher Scientific ( PPD Laboratory Services ): Global leader in mass spectrometry instrumentation and proteomics services through its PPD clinical research business and Thermo Fisher Scientific's broader analytical services. Provides significant competitive scale advantage in the same market.
• Bruker Corporation: Mass spectrometry instrumentation provider that has expanded into proteomics services including timsTOF-based proteomics offerings. Both an equipment supplier and increasingly a service provider competitor in proteomics.

Direct peers

• Biognosys: Swiss-based proteomics CRO offering mass spectrometry-based services for drug discovery and biomarker development, including DIA-based proteomics platforms. Most directly comparable peer given similar technology stack and customer base of pharma and biotech clients.
• Reaction Biology: Preclinical CRO offering protein-based services including kinase profiling, selectivity screening, and biophysical assays. Overlaps with KinomeScout and TargetScout offerings for pharma drug discovery clients.
• Caprion Biosciences: Specialized proteomics and immune monitoring CRO serving biopharma clients with mass spectrometry-based biomarker discovery and target identification services. Comparable in scale and customer focus to OmicScouts.

Emerging players

• Promega Corporation: Provider of proteomics tools and reagents with growing service offerings. Member of the ZIM Proteomics4Future network alongside OmicScouts, indicating direct competitive overlap in technology development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/omicscouts

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OmicScouts